Boston Scientific Corp. stock outperforms competitors
Boston Scientific Corp. stock underperforms Tuesday when compared to competitors
Boston Scientific Corp. closed $1.60 below its 52-week high ($84.12), which the company achieved on September 13th.
Here's Why Boston Scientific (BSX) is a Strong Growth Stock
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The research service features daily updates of the Zacks Rank and Zacks Industry Rank,
Pick Boston Scientific Stock After 130% Gains?
Investors have rewarded BSX stock thanks to the uptick in its sales for its new products and the Watchman line.
Boston Scientific Corp. stock underperforms Monday when compared to competitors despite daily gains
Boston Scientific Corp. closed $0.61 short of its 52-week high ($84.12), which the company reached on September 13th.
Boston Scientific Corporation (BSX) Stock: Beyond the Surface of Its Performance?
Boston Scientific Corporation (BSX) stock saw a decline, ending the day at $82.52 which represents a decrease of $-0.99 or -1.19% from the prior close of $83.51. The stock opened at $83.33 and touched a low of $81.
What's Behind The 2x Rise In Boston Scientific Stock?
We estimate Boston Scientific’s Valuation to be $83 per share, aligning with its current levels of $82. At its current levels, BSX stock is trading at 8.2x revenues. The 8.2x figure is higher than the stock’s average P/S ratio of 5.
Boston Scientific Corp. stock outperforms competitors despite losses on the day
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with unparalleled accuracy. Back To Top
Boston Scientific: Forward Returns Are Likely To Be Disappointing For Investors
Boston Scientific's earnings growth may slow to the low teens, making current P/E multiples hard to justify. See why BSX ...
Boston Scientific has prostate cancer solutions at Valley Urologic Associates
((SL Advertiser)) Boston Scientific has prostate cancer solutions at Valley Urologic Associates. To learn more, go to ...
WBJournal2d
Boston Scientific closes $1.2B acquisition of California stroke prevention device maker
Boston Scientific, a Marlborough medical device manufacturer, has officially closed its acquisition of California medical ...
MassDevice3d
FDA approves expanded label for Boston Scientific Ingevity+ pacing leads
Boston Scientific (NYSE: BSX) received FDA approval to expand the indication for its current-generation Ingevity+ pacing ...
Business Insider1d
Analysts’ Top Healthcare Picks: TG Therapeutics (TGTX), Boston Scientific (BSX)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on TG Therapeutics (TGTX – Research Report) and Boston Scientific (BSX – Research Report) with bullish ...
GlobalData on MSN2d
Boston Scientific expands FDA label for Ingevity+ pacing leads
The expanded indication includes conduction system pacing (CSP) and sensing of the left bundle branch area (LBBA) for use ...
MassDevice3d
Boston Scientific closes Silk Road Medical acquisition
Boston Scientific (NYSE: BSX) announced today that it completed its $1.16 billion acquisition of Silk Road Medical ...
Boston Scientific’s Buy Rating: TAVR Developments Signal Market Growth and Revenue Potential
Bank of America Securities analyst Travis Steed has maintained their bullish stance on BSX stock, giving a Buy rating on September 5. Travis ...